Antengene's Breakthrough Clinical Study Results at ASH 2024
Antengene Corporation Limited, a prominent global biopharmaceutical company, recently showcased its innovative advancements at the prestigious American Society of Hematology Annual Meeting. The latest research is centered around the promising compound selinexor, which has been the focus of two late-stage clinical studies. This event marks a significant opportunity for Antengene to highlight its dedication to enhancing patient care through cutting-edge therapies for hematologic malignancies.
Overview of the Clinical Studies
Two key posters presented by Antengene detail the findings from these clinical trials. The first study investigates the combination of selinexor with bortezomib and dexamethasone in Chinese patients diagnosed with relapsed and refractory multiple myeloma (RRMM). This Phase III BENCH study aims to determine if the new treatment regimen enhances efficacy compared to the standard bortezomib and dexamethasone regimen. The second study focuses on selinexor combined with tislelizumab for patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL).
Insights from the BENCH Study
The BENCH study is notable for its comprehensive design. Enrolling over 150 participants, the trial compared the safety and efficacy of the selinexor-containing regimen against the conventional treatment. Initial findings indicate that patients on the selinexor regimen experience a median progression-free survival (mPFS) of 8.1 months, a notable advancement compared to 6.3 months in the standard group.
- Of significance, the study's results reveal that treatment with selinexor resulted in a higher overall response rate (ORR) among patients, highlighting its potential to offer better outcomes. In addition, it was observed that patients treated with selinexor had a significantly higher rate of achieving a very good partial response (VGPR).
- The safety profile of selinexor was also favorable, with fewer instances of severe peripheral neuropathy reported compared to traditional treatments, indicating a more manageable side effect profile.
Selinexor and Tislelizumab: New Frontiers in Treatment
The second poster presented by Antengene showcased preliminary data from its TOUCH study, exploring the safety and efficacy of selinexor in combination with the anti-PD-1 antibody, tislelizumab. The aim was to deliver a non-chemotherapy regimen that provides patients with effective treatment options, particularly those exhibiting resistance to standard therapies.
- Initial results from this cohort of patients indicate a striking overall response rate of 75%, demonstrating substantial clinical benefit. The data suggest that such combinations may reverse drug resistance, presenting a therapeutic avenue for challenging cases of ENKTL.
About Antengene Corporation
Antengene Corporation Limited, listed on the Hong Kong Stock Exchange under the ticker SEHK: 6996.HK, has established itself as a leader in the biopharmaceutical sector. Its mission, "Treating Patients Beyond Borders," underscores the company's commitment to global health. With an extensive pipeline of nine oncology assets that are in various stages of development, Antengene has achieved numerous investigational new drug (IND) approvals across numerous markets.
As the company expands its influence in the Asia-Pacific region and beyond, Antengene remains steadfast in its goal to create innovative treatment solutions aimed at improving patient outcomes in hematologic malignancies and solid tumors.
Frequently Asked Questions
What is the focus of the studies presented by Antengene?
The studies focus on the efficacy and safety of selinexor combined with other agents for treating multiple myeloma and NK/T-cell lymphoma.
What were the findings related to the BENCH study?
Findings from the BENCH study suggest that selinexor provides improved progression-free survival and response rates compared to traditional therapies.
How does the combination of selinexor and tislelizumab impact patients?
The combination has shown to yield a high overall response rate and may help overcome drug resistance in patients with R/R ENKTL.
What is Antengene's mission?
Antengene's mission is dedicated to the vision of treating patients across borders, emphasizing its global outreach in healthcare.
How many drug approvals has Antengene achieved?
Antengene has obtained 31 IND approvals and submitted ten NDAs in various markets, underscoring its focus on global clinical development.
